Arcus Biosciences Stock Today
| RCUS Stock | USD 8.59 0.12 1.42% |
PerformanceModest
| Odds Of DistressLow
|
Arcus Biosciences is selling for under 8.59 as of the 4th of July 2025; that is 1.42 percent increase since the beginning of the trading day. The stock's lowest day price was 8.3. Arcus Biosciences has about a 23 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 9th of July 2024 and ending today, the 4th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of March 2018 | Category Healthcare | Classification Health Care |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company was incorporated in 2015 and is headquartered in Hayward, California. Arcus Biosciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. The company has 105.89 M outstanding shares of which 10.47 M shares are at this time shorted by private and institutional investors with about 9.05 trading days to cover. More on Arcus Biosciences
Moving together with Arcus Stock
Moving against Arcus Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Arcus Stock Highlights
| Chairman | Terry Rosen | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, SP Small-Cap 600, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsArcus Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Arcus Biosciences' financial leverage. It provides some insight into what part of Arcus Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Arcus Biosciences (RCUS) is traded on New York Stock Exchange in USA. It is located in 3928 Point Eden Way, Hayward, CA, United States, 94545 and employs 627 people. Arcus Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 896.85 M. Arcus Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 105.89 M outstanding shares of which 10.47 M shares are at this time shorted by private and institutional investors with about 9.05 trading days to cover.
Arcus Biosciences currently holds about 1.05 B in cash with (170 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Arcus Biosciences Probability Of Bankruptcy
Ownership AllocationArcus Biosciences holds a total of 105.89 Million outstanding shares. Over half of Arcus Biosciences' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Arcus Ownership Details
Arcus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Parkman Healthcare Partners Llc | 2025-03-31 | 1.2 M | |
| Millennium Management Llc | 2025-03-31 | 1.2 M | |
| Ra Capital Management, Llc | 2025-03-31 | 1.1 M | |
| Wellington Management Company Llp | 2025-03-31 | 1.1 M | |
| Sofinnova Ventures | 2025-03-31 | 1 M | |
| Jacobs Levy Equity Management, Inc. | 2025-03-31 | 972.2 K | |
| Goldman Sachs Group Inc | 2025-03-31 | 914.2 K | |
| Decheng Capital Llc | 2025-03-31 | 808.8 K | |
| Morgan Stanley - Brokerage Accounts | 2025-03-31 | 787.1 K | |
| Blackrock Inc | 2025-03-31 | 10.9 M | |
| Vanguard Group Inc | 2025-03-31 | 6.7 M |
Arcus Biosciences Historical Income Statement
Arcus Stock Against Markets
Arcus Biosciences Corporate Directors
| Patrick Machado | Independent Director | Profile | |
| Antoni Ribas | Independent Director | Profile | |
| Andrew Perlman | Independent Director | Profile | |
| Yasunori Kaneko | Lead Independent Director | Profile |
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.